Viveve Medical

General Information

(Note – a public offering: Its common stock has been traded on the OTCQB under the symbol “VIVMF” since 2010. )

We design, develop, manufacture and market medical devices for the non-invasive treatment of vaginal laxity. Vaginal laxity occurs in many women as a result of natural childbirth, during which the vaginal opening, or introitus, is over-stretched and fails to return to its pre-childbirth state. Vaginal laxity can often cause decreased sexual function and satisfaction in women. The Viveve Treatment is a non-invasive solution for vaginal laxity that is performed in less than 30 minutes, in a physician’s office, and does not require the use of anesthesia. The Viveve System uses patented monopolar radiofrequency, or RF, energy to generate low temperature heat. The vaginal mucosa is simultaneously cooled while this non-ablative heat is delivered into the submucosal layer.

Employees: 23
Founded: 2005
Contact Information
Address 150 Commercial Street, Sunnyvale, CA 94086, US
Phone Number (408) 530-1900
Web Address
View Prospectus: Viveve Medical
Financial Information
Market Cap $76.8mil
Revenues $2.7 mil (last 12 months)
Net Income $-14.0 mil (last 12 months)
IPO Profile
Symbol VIVE
Exchange NASDAQ
Shares (millions): 2.7
Price range $5.00 - $5.00
Est. $ Volume $13.5 mil
Manager / Joint Managers Ladenburg Thalmann/ Craig-Hallum Capital Group
CO-Managers Maxim Group
Expected To Trade: 6/14/2016
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change